Build, Convert, or Ring Fence: The First Decision in a Hospital Longevity Clinic
Founder & Managing Partner
Kamal Hassan is the Founder & Managing Partner of TURN8 — the venture operating partner for GCC corporates and sovereign-linked institutions. With 30+ years of experience across the United States, MENA, and Europe, Kamal has built a rare track record at the intersection of corporate innovation, venture capital, and operational execution.
For a hospital group evaluating a longevity clinic, the first decision is not where to put it. It is which entry route the group is buying, and how much capital that route puts at risk before the model is proven. That decision belongs before site selection and before capital approval. It is expensive to discover halfway through a build.
Longevity clinics rarely fail for clinical reasons
In our experience the failure is structural. Four patterns account for most of it.
The first is capitalizing at steady state. A full clinical, digital, and commercial team is hired to run a mature operation before demand is validated. Payroll runs at scale while revenue does not.
The second is scaling footprint before retention. A second and third site are committed while repeat engagement is still unproven. Footprint is the most expensive way to test demand.
The third is diagnostics heavy and intervention light. Capital concentrates in imaging and panels with no governed intervention loop behind them. Members complete a baseline, receive a report, and leave.
The fourth is service line framing. The clinic runs as a hospital department rather than a venture with its own profit and loss. Unit economics are never visible, so the business cannot be judged, defended, or fixed.
None of these are clinical problems. All four are decided before a single patient is seen.
These patterns are not theoretical. A well funded preventive health venture wound down earlier this year, closing its clinics after a short run and telling members it had not managed to build a sustainable business. The name is not the instructive part. The structure is. It stood up the full fixed cost of physical delivery across more than one location before either had time to show that members come back, and it did so against venture expectations on a venture clock.
What a hospital group already owns
A hospital group already holds most of what a longevity venture needs, and it holds the expensive part. Accredited diagnostic capacity. Specialists across disciplines. Rehabilitation and nutrition. Follow up care. Clinical governance and a licensed environment to run it in.
That is years of capital and regulatory work already absorbed. A new entrant starts by buying all of it.
What is usually missing is commercial, not clinical
Most groups answer this question with their executive health program. Executive health is the strongest available starting asset, and the answer is not to dismiss it.
It is a product rather than a business. It measures a patient once and issues a report. A membership holds a member for years and sells against a measured trajectory. Those are different revenue models, different retention economics, and different operating requirements.
The gap is commercial and structural. Closing it is not a matter of adding a service or coordinating a pathway between departments that already exist.
Three entry routes, in ascending order of capital
Convert the existing executive health unit into an annual program with scheduled re-measurement, physician owned interpretation, and a governed intervention library above the panels the group already runs. Lowest capital, fastest evidence, weakest pricing power.
Ring fence a unit on campus with its own entrance, brand, and profit and loss. The clinical backbone stays shared. The venture becomes separately measurable, which is the point.
Build a standalone member clinic off campus against the group’s clinical governance and diagnostic backbone. Highest capital, highest pricing power, and the route that punishes a wrong assumption hardest.
Capital at risk and pricing power rise together across the three. There is no route that gives one without the other.
The decision that makes a build an asset or a liability
A new build can be the right answer. It should not be the first assumption, and it should not be run as a department.
A service line build commits full capital before validation, hires the full team before the model is proven, and carries a single J curve with no gates. It produces an expensive clinic. It cannot be refinanced or attract co-investment.
A venture build gates capital against evidence milestones, validates each engine independently, brings clinical authority in from day one, and treats the member record as a compounding asset rather than a results archive. It produces a company that can be funded, partnered, or scaled.
Same clinical ambition. Different structure. Different outcome.
Frequently Asked Questions
Why do longevity clinics usually fail?
Rarely for clinical reasons. The common causes are structural: capitalizing at steady state before demand is validated, scaling footprint before retention is proven, concentrating capital in diagnostics without a governed intervention loop, and running the clinic as a hospital department rather than a venture with its own profit and loss.
What does a hospital group already have that a new longevity venture would need to build from zero?
Accredited diagnostic capacity, specialists, rehabilitation, nutrition, follow up care, clinical governance, and a licensed environment. That is the expensive part, and a new entrant has to buy all of it.
Is an executive health program enough to launch a longevity offering?
It is the strongest starting asset, but it is a product rather than a business. It measures a patient once and issues a report. A membership holds a member for years and sells against a measured trajectory. The gap between the two is commercial and structural rather than clinical.
What are the entry routes for a hospital group?
Three, in ascending order of capital. Convert the existing executive health unit into an annual membership program. Ring fence a unit on campus with its own entrance, brand, and profit and loss. Build a standalone member clinic off campus against the group’s clinical governance and diagnostic backbone. Capital at risk and pricing power rise together.
When should the build versus convert decision be made?
Before site selection and before capital approval. Reversing course partway through construction is the most expensive version of this decision.
Who should make the decision?
The hospital group CEO, CMO, and Chief Strategy Officer, together, because the decision is commercial, clinical, and structural at the same time.